Development of an Adverse Drug Event Network to Predict Drug Toxicity

Overview

Journal Curr Res Toxicol

Specialty Biology

Date 2021 Aug 4

PMID 34345836

Citations 1

Authors

Qier Wu

Olivier Taboureau

Karine Audouze

Affiliations

Soon will be listed here.

Abstract

Despite of their therapeutic effects, drug's exposure may have negative effects on human health such as adverse drug reaction (ADR) and side effects (SE). Adverse drug events (ADEs), that correspond to an event occurring during the drug treatment (i.e. ADR and SE), is not necessarily caused by the drug itself, as this is the case with medical errors and social factors. Due to the complexity of the biological systems, not all ADEs are known for marketed drugs. Therefore, new and effective methods are needed to determine potential risks, including the development of computational strategies. We present an ADE association network based on 90,827 drug-ADE associations between 930 unique drug and 6221 unique ADE, on which we implemented a scoring system based on a pull-down approach for prediction of drug-ADE combination. Based on our network, ADEs proposed for three drugs, safinamide, sonidegib, rufinamide are further discussed. The model was able to identify, already known drug-ADE associations that are supported by the literature and FDA reports, and also to predict uncharacterized associations such as dopamine dysregulation syndrome, or nicotinic acid deficiency for the drugs safinamide and sonidegib respectively, illustrating the power of such integrative toxicological approach.

Citing Articles

DrugCentral 2021 supports drug discovery and repositioning.

Avram S, Bologa C, Holmes J, Bocci G, Wilson T, Nguyen D Nucleic Acids Res. 2020; 49(D1):D1160-D1169.

PMID: 33151287 PMC: 7779058. DOI: 10.1093/nar/gkaa997.

References

Marquet A, Kupas K, Johne A, Astruc B, Patat A, Krosser S . The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther. 2012; 92(4):450-7. DOI: 10.1038/clpt.2012.128. View

FitzGerald G . Coxibs and cardiovascular disease. N Engl J Med. 2004; 351(17):1709-11. DOI: 10.1056/NEJMp048288. View

Bloomingdale P, Housand C, Apgar J, Millard B, Mager D, Burke J . Quantitative systems toxicology. Curr Opin Toxicol. 2018; 4:79-87. PMC: 5754001. DOI: 10.1016/j.cotox.2017.07.003. View

Ho Y, Gruhler A, Heilbut A, Bader G, Moore L, Adams S . Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature. 2002; 415(6868):180-3. DOI: 10.1038/415180a. View

Anasti J . Premature ovarian failure: an update. Fertil Steril. 1998; 70(1):1-15. DOI: 10.1016/s0015-0282(98)00099-5. View

Devinsky O, Gazzola D, LaFrance Jr W . Differentiating between nonepileptic and epileptic seizures. Nat Rev Neurol. 2011; 7(4):210-20. DOI: 10.1038/nrneurol.2011.24. View

Singh G, Hernaiz Driever P, Sander J . Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain. 2004; 128(Pt 1):7-17. DOI: 10.1093/brain/awh363. View

Berger S, Iyengar R . Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip Rev Syst Biol Med. 2010; 3(2):129-35. PMC: 3057924. DOI: 10.1002/wsbm.114. View

Chen X, Liu X, Jia X, Tan F, Yang R, Chen S . Network characteristic analysis of ADR-related proteins and identification of ADR-ADR associations. Sci Rep. 2013; 3:1744. PMC: 3638162. DOI: 10.1038/srep01744. View

10.

Lavan A, Gallagher P . Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016; 7(1):11-22. PMC: 4716390. DOI: 10.1177/2042098615615472. View

11.

Uchegbu I, Florence A . Adverse drug events related to dosage forms and delivery systems. Drug Saf. 1996; 14(1):39-67. DOI: 10.2165/00002018-199614010-00005. View

12.

Gaudineau C, Auclair K . Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem Biophys Res Commun. 2004; 317(3):950-6. DOI: 10.1016/j.bbrc.2004.03.137. View

13.

Ciallella H, Zhu H . Advancing Computational Toxicology in the Big Data Era by Artificial Intelligence: Data-Driven and Mechanism-Driven Modeling for Chemical Toxicity. Chem Res Toxicol. 2019; 32(4):536-547. PMC: 6688471. DOI: 10.1021/acs.chemrestox.8b00393. View

14.

Frid A, Matthews E . Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities. Regul Toxicol Pharmacol. 2009; 56(3):276-89. DOI: 10.1016/j.yrtph.2009.11.005. View

15.

Dix D, Houck K, Martin M, Richard A, Setzer R, Kavlock R . The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci. 2006; 95(1):5-12. DOI: 10.1093/toxsci/kfl103. View

16.

Morrow E, Lafayette J, Bromfield E, Fricchione G . Postictal psychosis: presymptomatic risk factors and the need for further investigation of genetics and pharmacotherapy. Ann Gen Psychiatry. 2006; 5:9. PMC: 1555577. DOI: 10.1186/1744-859X-5-9. View

17.

Crome P . The toxicity of drugs used for suicide. Acta Psychiatr Scand Suppl. 1993; 371:33-7. DOI: 10.1111/j.1600-0447.1993.tb05371.x. View

18.

Stathias V, Turner J, Koleti A, Vidovic D, Cooper D, Fazel-Najafabadi M . LINCS Data Portal 2.0: next generation access point for perturbation-response signatures. Nucleic Acids Res. 2019; 48(D1):D431-D439. PMC: 7145650. DOI: 10.1093/nar/gkz1023. View

19.

Rugard M, Coumoul X, Carvaillo J, Barouki R, Audouze K . Deciphering Adverse Outcome Pathway Network Linked to Bisphenol F Using Text Mining and Systems Toxicology Approaches. Toxicol Sci. 2019; 173(1):32-40. PMC: 6944215. DOI: 10.1093/toxsci/kfz214. View

20.

Bauer J . Seizure-inducing effects of antiepileptic drugs: a review. Acta Neurol Scand. 1996; 94(6):367-77. DOI: 10.1111/j.1600-0404.1996.tb00047.x. View